Discovery Platform

Sapience programs focus on discovery and development of peptides that act at the level of transcriptional regulation of oncogenic and immune-modulatory proteins by disrupting protein-protein interactions. Sapience has multiple approaches to discovering these new molecular entities, including our library-based platform screen that uses Protein Fragment Complementation enhanced with a Competitive and Negative Design Initiative (PCA-CANDI) that we run in partnership with the University of Bath, and our Knowledge Based Design Initiative (KBDI).

PCA-CANDI

Protein fragment complementation that incorporates competitive and negative design elements allows for rapid discovery of peptide disrupters of specific protein-protein interactions.

ST201 emerged from the PCA-CANDI platform.

Schematic of PCA:

Knowledge Based Design Initiative

Rational design of peptide libraries to disrupt protein-protein interactions; the basis of which may be 3D modeling or hits from PCA-CANDI.

ST101 is an example of Sapience’s KBDI. It was discovered and initiated IND-enabling manufacturing within 9 months of library initiation.

Schematic of KBDI: